A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

Clinical trial NCT06624644 · RECRUITING

Trial details

NCT number: NCT06624644
Sponsor: Linnaeus Therapeutics, Inc.
Status: RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Melanoma (Skin Cancer)Melanoma Stage IIIB-IV Cutaneous Melanoma Unresectable Melanoma

Start date: 2025-08-06
Primary completion: 2029-02-01
Enrollment: 135

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.